Quick answer: Alzheimer’s disease affects 6.7 million Americans and is projected to reach 13 million by 2050, yet it remains one of the few major diseases with no approved disease-modifying treatment. Dale Bredesen’s RECODE protocol — the first clinical approach to show cognitive reversal in documented Alzheimer’s patients — targets 36 metabolic, hormonal, inflammatory, toxin, and nutritional drivers of neurodegeneration. Functional neurology combines the RECODE framework with BDNF optimization, neuroinflammation assessment, methylation support, and precision lifestyle protocols to prevent, slow, and in early cases reverse cognitive decline.
Conventional neurology offers disease categorization — MCI, early AD, moderate AD — and symptomatic management with cholinesterase inhibitors showing modest, temporary benefits. The lecanemab era (FDA-approved 2023) addresses amyloid accumulation but shows only modest slowing of decline in carefully selected patients, with significant side effects. The deeper question — why is amyloid accumulating in the first place, and what biological insults are driving neurodegeneration — is precisely what functional neurology addresses.
The RECODE Protocol: 36 Drivers of Alzheimer’s Disease
Dale Bredesen, MD published the first case series of cognitive reversal in Alzheimer’s patients in 2014 (Aging), followed by larger cohorts (Bredesen 2016, Aging; Bredesen et al. 2018, Journal of Alzheimer’s Disease) demonstrating that a comprehensive, individualized protocol targeting multiple upstream drivers could achieve cognitive improvement in early-stage AD — unprecedented in the history of Alzheimer’s treatment. The protocol identifies 36 metabolic factors that collectively damage and fail to repair synaptic connections, and addresses them in a personalized, data-driven way.
The three subtypes of Alzheimer’s in the RECODE framework: (1) Type 1 — Inflammatory (“hot”): driven by chronic systemic inflammation (elevated hs-CRP, IL-6, TNF-α), often associated with APOE4 allele, which impairs amyloid clearance and amplifies neuroinflammation. (2) Type 2 — Atrophic (“cold”): driven by trophic factor withdrawal — reduced BDNF, low sex hormones, low thyroid, insulin resistance, and nutrient deficiencies that deprive neurons of growth signals. (3) Type 3 — Toxic (“vile”): driven by heavy metals (mercury, lead, copper/zinc imbalance), mycotoxins from mold exposure, organic toxins (toluene, benzene), and biotoxins — often presenting earlier (50s) and in individuals without strong family history. Each subtype requires different primary interventions.
Key RECODE assessment biomarkers: fasting insulin and HOMA-IR (insulin resistance is the most consistently modifiable AD risk factor); hemoglobin A1c; 25-OH vitamin D; omega-3 index; homocysteine (>10 µmol/L is a major modifiable risk factor); B12 (methylcobalamin); folate; hs-CRP; IL-6; fasting thyroid panel including free T3 and reverse T3; sex hormones (estradiol, progesterone, testosterone, DHEA-S); pregnenolone; APOE genotype; heavy metal testing; mycotoxin panel; and complete metabolic panel including LFTs (liver supporting Phase II detoxification).
BDNF: The Master Trophic Factor for Neuroplasticity and Cognitive Reserve
Brain-derived neurotrophic factor (BDNF) is the most important trophic signal in the adult brain — promoting neuronal survival, synaptic plasticity, memory consolidation, and adult neurogenesis in the hippocampus. BDNF binds TrkB receptors to activate MAPK/ERK (cell survival), PI3K/Akt (anti-apoptosis), and PLCγ (synaptic plasticity) pathways. Serum BDNF is significantly lower in Alzheimer’s disease, MCI, depression, insulin resistance, and sedentary individuals. The Val66Met BDNF polymorphism — present in 25% of Europeans — impairs activity-dependent BDNF secretion and is associated with increased AD risk and poor response to trophic stimulation.
The most powerful BDNF inducers are evidence-based and modifiable. Exercise is the gold standard: Cotman and Berchtold (2002, Trends in Neurosciences) established that aerobic exercise reliably increases hippocampal BDNF, promotes neurogenesis, and improves cognitive function. Erickson et al. (2011, PNAS) conducted an RCT showing 1 year of aerobic exercise increased hippocampal volume by 2% in previously sedentary older adults — reversing approximately 1–2 years of age-related hippocampal atrophy — with BDNF increase mediating the effect. Resistance training also increases BDNF and shows independent neuroprotective effects through IGF-1 and FNDC5/irisin signaling. Caloric restriction and intermittent fasting upregulate BDNF through AMPK and SIRT1 activation. Cognitive enrichment — learning new skills, social engagement — drives activity-dependent BDNF release. Omega-3 DHA supplementation increases hippocampal BDNF in animal models. Lion’s mane mushroom (Hericium erinaceus) produces hericenones and erinacines that cross the blood-brain barrier and stimulate Nerve Growth Factor (NGF) and BDNF synthesis: Mori et al. (2009, Phytotherapy Research) RCT showed significant improvement in cognitive function scores in MCI patients taking lion’s mane (3g/day) vs. placebo at 16 weeks.
Neuroinflammation: The Common Driver of All Neurodegenerative Disease
Neuroinflammation — chronic, low-grade activation of brain microglia and astrocytes — is the final common pathway driving neurodegeneration across Alzheimer’s, Parkinson’s, MS, ALS, and traumatic brain injury sequelae. Microglia are the brain’s resident immune cells; when chronically activated by systemic inflammation, amyloid, damaged myelin, or toxins, they switch from neuroprotective (M2 state) to neurotoxic (M1 state), releasing glutamate, reactive oxygen species, and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) that damage synapses and kill neurons. The NLRP3 inflammasome in microglia processes IL-1β and drives amyloid plaque formation — making neuroinflammation both a cause and consequence of Alzheimer’s pathology in a self-amplifying cycle.
Systemic inflammatory drivers that chronically activate microglia: peripheral LPS from gut dysbiosis (gut-brain axis); herpesvirus reactivation (HSV-1 infects hippocampal neurons and triggers Aβ production as an antiviral defense — Itzhaki et al., multiple papers, 1991–2018); chronic dental infections and periodontal pathogens (Porphyromonas gingivalis detected in Alzheimer’s brain tissue — Dominy et al. 2019, Science Advances); mold toxins (mycotoxins cross the blood-brain barrier and activate microglial NLRP3); heavy metal accumulation (mercury activates microglia directly); sleep deprivation (glymphatic system, which clears amyloid during sleep, is impaired). The glymphatic system — discovered by Maiken Nedergaard (2013, Science) — is the brain’s lymphatic equivalent, activated during slow-wave sleep, that clears amyloid and tau. Chronic poor sleep doubles amyloid accumulation rate (Lucey et al. 2021, Brain).
Neuroinflammation biomarkers accessible in clinical practice: plasma neurofilament light chain (NfL) — a marker of neuronal damage — is elevated in AD, Parkinson’s, MS, and traumatic brain injury, and predicts cognitive decline years before symptoms; plasma GFAP (glial fibrillary acidic protein) reflects astrocyte activation; systemic hs-CRP and IL-6 as peripheral inflammatory proxies; homocysteine (above 10 µmol/L directly toxic to neurons through NMDA excitotoxicity); and LPS-binding protein or anti-LPS IgG as gut-permeability markers indicating endotoxemia driving microglial activation via the gut-brain axis.
Insulin Resistance and the Alzheimer’s-Diabetes Connection
Alzheimer’s disease is now often described as “Type 3 diabetes” — a term reflecting the central role of insulin signaling impairment in AD pathophysiology. The brain is insulin-sensitive, requiring insulin signaling for glucose transport, BDNF production, amyloid clearance (through insulin-degrading enzyme, IDE, which degrades both insulin and amyloid-β), and synaptic plasticity. Insulin resistance in the brain reduces IDE activity, impairing amyloid clearance; reduces BDNF expression; and increases tau phosphorylation through GSK-3β activation — connecting metabolic syndrome directly to the core pathological features of Alzheimer’s. de la Monte et al. (2009, Journal of Alzheimer’s Disease) established the molecular basis of brain insulin resistance in AD, showing dramatically reduced insulin receptor expression and downstream signaling in AD brains compared to controls.
The interventional implications are significant: addressing insulin resistance through time-restricted eating, low-glycemic diet, exercise, berberine, and — in selected patients — GLP-1 agonists, directly targets a central driver of AD. Craft et al. (2012, Archives of Neurology) showed intranasal insulin (bypassing systemic metabolism) improved memory and cognition in MCI and early AD — providing direct evidence that insulin signaling in the brain is causally linked to cognitive function. Metabolic monitoring (fasting insulin, HOMA-IR, HbA1c, CGM data) should be standard in any cognitive decline evaluation.
Frequently Asked Questions About Functional Neurology
What is the RECODE protocol?
RECODE (REversal of COgnitive DEcline) is a comprehensive, individualized protocol developed by Dr. Dale Bredesen targeting the 36 metabolic, inflammatory, hormonal, nutritional, and toxicological drivers of Alzheimer’s disease. Unlike pharmaceutical approaches targeting a single mechanism, RECODE uses detailed biomarker assessment to identify each patient’s specific combination of drivers and addresses them simultaneously through diet (ketogenic-leaning, low-glycemic), exercise, sleep optimization, stress reduction, hormonal optimization, micronutrient correction, detoxification, and infection treatment. Multiple case series show cognitive improvement in early-stage Alzheimer’s patients on the RECODE protocol.
What are the early warning signs of cognitive decline that functional medicine can identify?
Functional medicine can identify pre-symptomatic cognitive risk through biomarkers that change years before clinical decline: elevated fasting insulin and HOMA-IR (insulin resistance is detectable 10–20 years before AD diagnosis); rising homocysteine above 10 µmol/L; declining BDNF; elevated hs-CRP; low 25-OH vitamin D; suboptimal omega-3 index; declining DHEA-S; sleep fragmentation reducing glymphatic amyloid clearance; and plasma NfL/GFAP elevation. APOE4 genotype identifies 25–30% of the population with 3–10x increased AD risk who benefit most from aggressive prevention. CNS Vital Signs or Cambridge Brain Sciences cognitive testing provides objective, annual cognitive tracking with normative comparisons.
Is Parkinson’s disease amenable to functional medicine approaches?
Yes. Parkinson’s disease increasingly recognized as having significant gut-brain axis involvement — the “Braak staging” hypothesis suggests PD pathology begins in the enteric nervous system (gut) and propagates via the vagus nerve to the brasal ganglia, years before motor symptoms. Constipation, SIBO, and altered gut microbiome composition precede PD diagnosis by 10–20 years. Interventions targeting the gut-brain axis (treating SIBO/dysbiosis, eliminating gut-derived LPS), reducing neuroinflammation (omega-3s, curcumin), optimizing mitochondrial function (CoQ10, NAD+, exercise), and addressing heavy metal burden (particularly manganese for parkinsonism) represent meaningful adjuncts to conventional dopaminergic therapy. Emerging evidence shows GLP-1 agonists may slow PD progression through neuroprotective mechanisms.
Can traumatic brain injury (TBI) sequelae be addressed functionally?
Post-concussion syndrome and chronic traumatic encephalopathy (CTE) risk involve persistent neuroinflammation, blood-brain barrier disruption, mitochondrial dysfunction, and tau accumulation. Functional approaches include: anti-inflammatory protocols (omega-3s — Lewis et al. showed high-dose DHA 10g/day reduced NfL in TBI); NAD+ repletion supporting neuronal energy metabolism; hyperbaric oxygen therapy (HBOT) — Harch et al. (2012) showed 40 sessions of 1.5 ATA HBOT improved cognitive and psychological symptoms in blast TBI; transcranial photobiomodulation (red/near-infrared light) stimulating mitochondrial cytochrome c oxidase in neurons; and sleep optimization to restore glymphatic tau clearance. APOE4 genotype significantly worsens TBI outcomes, and APOE4 carriers with TBI history warrant aggressive neuroinflammation management.
The Functional Neurology Assessment and Protocol
Comprehensive functional neurology assessment begins with objective cognitive testing (CNS Vital Signs, Cambridge Brain Sciences, or equivalent computerized battery providing normative scoring), followed by the full RECODE biomarker panel: metabolic (fasting glucose, insulin, HOMA-IR, HbA1c), inflammatory (hs-CRP, IL-6, homocysteine), hormonal (TSH, free T3, free T4, estradiol, testosterone, DHEA-S, pregnenolone), nutritional (vitamin D, B12, folate, zinc, magnesium, omega-3 index, CoQ10), genetic (APOE4, MTHFR, COMT — the methylation gene affecting dopamine/norepinephrine metabolism and stress response), toxicological (heavy metals — mercury, lead, arsenic; mycotoxins if history of mold exposure), and neurodegeneration markers (plasma NfL, GFAP where accessible).
The protocol is individualized based on findings but consistently includes: metabolic optimization (insulin sensitization through diet and exercise); sleep restoration targeting 7–9 hours with adequate slow-wave and REM sleep for glymphatic function; high-intensity exercise (BDNF induction) combined with resistance training (IGF-1/irisin pathway); ketogenic-leaning dietary pattern (providing ketone bodies as alternative neural fuel bypassing impaired glucose transport); targeted supplementation (lion’s mane, bacopa, phosphatidylserine, omega-3 DHA 2g/day, B complex with L-methylfolate and methylcobalamin, magnesium L-threonate for brain penetration); hormonal optimization to youthful ranges; and detoxification if indicated. Each intervention is monitored with quarterly biomarker reassessment and annual cognitive testing. The goal is to add to the patient’s cognitive reserve faster than neurodegeneration depletes it.
Cognitive decline is one of the most feared aspects of aging — and one of the most preventable when addressed early with a comprehensive functional medicine approach. If you are concerned about your cognitive trajectory, want to assess your Alzheimer’s risk factors, or are seeking a RECODE-informed evaluation of cognitive symptoms, call The Private Practice at (810) 206-1402 to schedule your functional neurology consultation.